Video: Firebrick Pharma (ASX:FRE) releases annual report and outlines growth plans

Firebrick Pharma has capped a successful year launching its product Nasodine Nasal Spray in the US, Singapore and will shortly launch in the Philippines in partnership with local pharmaceutical firm S.V More. The Philippines approach highlights a new business model for the Company where the aim is to partner Nasodine products and provide the partner with the right to manufacture locally, reducing costs for Firebrick. Executive Chairman, Dr Peter Molloy reveals what's in store for the Australian pharmaceutical innovator.